Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. - Wikidata - awgldk - TriplyDB

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

http://www.wikidata.org/entity/Q34716574

about

Risk Stratification in Differentiated Thyroid Cancer: An Ongoing Process BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications.NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer.Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma Biomarker-based prognostic stratification of young adult glioblastoma Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma - challenging the roles of Snail and E-Cadherin?Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer.BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.Sorafenib for the treatment of thyroid cancer: an updated review.Proteome analysis in thyroid pathology.The diagnostic and prognostic role of liquid-based cytology: are we ready to monitor therapy and resistance?BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.Decade in review-thyroid disease: The endocrinology of thyroid disease from 2005 to 2015.Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?A-Raf: A new star of the family of raf kinases.

P2860

Q26765083-B922D8B4-9A2A-4907-8A27-9BD009D16670 Q28075975-662925C5-C9EC-4D2A-9309-2FFA4CF4B64E Q30364216-AD0A73C6-3E40-407B-926E-7EC0AF9AB90E Q31114420-5FF0FCAD-66F5-460F-B67E-5A6B62314720 Q33558907-12058F20-36BF-42CF-97D0-FB3BF29EE0B3 Q33587905-B2FF5F8E-ED22-4EFB-9CCB-BD63A4EE4D64 Q33656624-CC84AC80-2A35-41B8-9B4E-EA7720B0200A Q33821945-B3AE7075-3F54-4E81-8B96-7E965CD98230 Q34509762-4683CE58-B12A-46F4-831A-CDABA174918A Q35543644-6D7FAEE6-B518-4523-A58A-D17B845F04DC Q35603183-3E130FAD-412A-4AA1-B25E-1C17D8FC527D Q35692478-16B61D61-4C40-43DE-96B1-DC2CF89DA201 Q35832157-E5A614C7-26BE-4BEE-AAB3-D64CD4F4D710 Q35906046-9188E432-6498-43F9-8845-FF46402A168A Q36012586-7EFBFF9B-89F6-42B0-8770-8878F1DFDF04 Q36014228-59A89A29-B8FB-4B1F-A55D-57A8D81420BF Q36016602-BC96EC76-8293-44E7-8022-ECD6BC0A9545 Q36339926-5F1955B8-AC9D-4285-8474-0D38F8F97B1D Q36431628-250B75DF-6541-4C58-8CED-BBBD275013BD Q36468764-B788E7C1-5ABA-4F4E-89D3-6B34810265D5 Q36565803-41D52587-B048-4A57-8965-8CF9D98A238C Q36566991-786093DA-49E4-4612-B41E-CDFA4D43A3BD Q36716977-3D22AB74-7DB8-4B88-A67C-0D17D38C4C2A Q36782664-4B335F09-0E79-47A4-9D41-961EF99477DC Q36962376-3CAD8CE8-BACB-4853-9618-802B214D4702 Q37097535-6AE69C41-26A1-417D-8C27-1B98D155C814 Q37109755-1BA50D5E-D5D4-49F3-A043-121AF1BE5577 Q37377544-145073FA-A1BE-45BF-B6F1-9646A3908522 Q37448258-D6D02208-805F-41EC-AD12-25062FF4279F Q37605033-337D73A4-9F83-4457-9F97-249D496241BB Q37624102-E4705E67-E1A3-4C56-8767-DB93E2F43262 Q37702207-216794C9-9A57-4B0C-8CEC-F38E0096F95C Q37702380-039D9D08-354E-441B-B0D1-2BE927251831 Q38326036-D8CCF761-AC24-46AB-B670-CC5737675C27 Q38541463-E0999277-B844-45C0-9118-977121D942B9 Q38552886-00D57EB5-691D-4694-BABA-04B819EFCD83 Q38566267-B2F8604B-5FD6-45FE-8C3B-7AF583060530 Q38599474-EED2D131-ED5E-4F37-8DBA-6A64A5156491 Q38614394-FB3826FB-2EC2-4778-B8A0-ACBFAB1EAAB9 Q38618036-7D679758-1471-45C2-A877-DBFDE2B261D5

P2860

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

http://www.wikidata.org/entity/Q34716574

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@ast

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@en

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@nl

type

label

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@ast

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@en

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@nl

prefLabel

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@ast

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@en

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

@nl

P1433

Q34716574-10F46024-E709-443A-B936-EECDBDD23663

P1476

Q34716574-E96E4DF2-B4F4-4AAA-9673-F28985451C42

P2093

Q34716574-199FD037-A425-4F15-BE34-E35BD436DAFC

Q34716574-2D99BC11-704F-4471-B4F2-F1722B5984F2

Q34716574-479CCE53-F003-49C7-BD01-3C868FF81B5D

Q34716574-53A3F4CB-DD3C-4FE6-97B1-B47D502ED3AC

Q34716574-5BEFDE08-DB4A-4EFD-B0F8-58688A9296D7

Q34716574-5D4AE27F-4EAC-47CF-845B-08CFFBC8B02A

Q34716574-701E6DFB-2B7B-4AD7-8592-0241D073E9D6

Q34716574-C43A58EE-AED3-40E1-8A34-A5111D5EB875

Q34716574-C6A7D046-0C5F-4248-87CC-B76FD673C81D

Q34716574-CF1E0403-AB9A-4757-9C42-36B613A39565

P2860

Q34716574-02CD93F5-2F40-4FB5-82B0-527BBA61A3BF

Q34716574-08E5AD55-E9CD-4233-890F-06049070451B

Q34716574-0A484EA6-EB4E-4BE2-AE70-4B8272F68CA0

Q34716574-15DA9189-AB41-4AB1-BBB6-32DAFB06D78D

Q34716574-173D4DB9-4385-43A1-AF6C-76653E1A9111

Q34716574-25FABF68-81D1-41C2-A745-F13A869B7434

Q34716574-28DDD67C-16DF-42D8-850D-5ADF27E9A88A

Q34716574-391E4120-5EA9-4CEC-9325-A7BBD87BCF38

Q34716574-3B8E7490-3441-4502-AA60-B91341A44551

Q34716574-493687ED-0CD8-4954-B1CC-258878A95154

P304

Q34716574-DEC48E1A-EC2B-4D83-843C-562EF9FD5DC2

P31

Q34716574-65F6B755-F258-4A4C-87D8-8492C83EFBDE

P356

Q34716574-55A90DCF-782E-4572-8BDF-2AA30FAC6DDC

P407

Q34716574-7AEF375E-89F1-4441-9EA0-96D574AEA5BB

P433

Q34716574-0B18FCE4-6CBA-479C-83C7-96F26718DA15

P478

Q34716574-98D0BA0D-2FF7-4646-8B24-366005987891

P50

Q34716574-07638CA1-01FE-4042-9ECE-37F016953255

Q34716574-1199C654-15E0-4A40-BED2-0D834A768274

Q34716574-1F9386DD-ED1F-40FB-8C2C-5002A93B8736

Q34716574-2B46CABB-5B4C-4740-B7B2-F1196397A537

Q34716574-2E14E7A2-8332-41E4-AA12-490B0614DD25

Q34716574-48014655-3CEA-4DC8-AEF0-D95DE1136A84

Q34716574-6E2FDC5E-ACEE-4F22-929A-526D8F9031EE

Q34716574-7F484754-CFFF-4838-B522-5E83E54983C0

Q34716574-8D6BCAB9-CF3F-412E-AB6C-4D2B34579259

Q34716574-9E82A0B5-1BA8-4AFB-8295-D5B6D2CE020F

P577

Q34716574-80BDD08F-AA16-4C9F-B8BA-2335C9F77585

P698

Q34716574-405E9FA5-DBA1-4F86-A0C7-D76DC15AB108

P932

Q34716574-E713FB87-AA02-4835-9EB8-FF2D9B78DBB2

P356

JCO.2014.56.8253

P1433

Journal of Clinical Oncology

P1476

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

@en

P2093

Agnieszka Czarniecka

http://www.w3.org/2001/XMLSchema#string

Ali S Alzahrani

http://www.w3.org/2001/XMLSchema#string

Bela Bendlová

http://www.w3.org/2001/XMLSchema#string

Christine J O'Neill

http://www.w3.org/2001/XMLSchema#string

Efisio Puxeddu

http://www.w3.org/2001/XMLSchema#string

Elizabeth H Holt

http://www.w3.org/2001/XMLSchema#string

Eyal Robenshtok

http://www.w3.org/2001/XMLSchema#string

Hirotaka Nakayama

http://www.w3.org/2001/XMLSchema#string

James A Fagin

http://www.w3.org/2001/XMLSchema#string

Kathryn A Carson

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Progress in molecular-based management of differentiated thyroid cancer

BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Controversies in primary treatment of low-risk papillary thyroid cancer.

Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns

Molecular pathogenesis and mechanisms of thyroid cancer

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

P304

42-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.56.8253

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Jarząb

Pilar Santisteban

Young Kee Shong

Giovanni Tallini

Alfred King-Yin Lam

Garcilaso Riesco-Eizaguirre

Rossella Elisei

Federica Vianello

P577

2014-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25332244

http://www.w3.org/2001/XMLSchema#string

P932

4268252

http://www.w3.org/2001/XMLSchema#string